Passage BIO PASG 深 沪
已收盘 08-15 16:00:00 美东时间
6.95
-0.640
-8.43%
华盛通- 最 高7.65
- 今 开7.47
- 成交量 6.17万股
- 最 低 6.79
- 昨 收 7.59
- 总市值 2168.61万
- 52周最高 26.60
- 市盈率 静 --
- 换手率 1.98%
- 52周最低 5.1239
- 委 比 98.02%
- 总股本 312.03万
- 历史最高 764.60
- 量 比 1.60
- 振 幅 11.33%
- 历史最低 5.14
- 每 手 1
- 风险率 0.30%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多美股机会日报丨“恐怖数据”符合预期，交易员下调美联储降息预期；巴菲特Q2新建仓股飙升，联合健康盘前涨超10%
“恐怖数据”符合预期，交易员下调美联储降息预期；巴菲特Q2新建仓股盘前飙升，联合健康涨超10%，纽柯钢铁涨近5%；美俄首脑即将举行会晤>>
08-15 20:49
美股大行评级 | 潜在涨幅仍有782.74%！Passage BIO遭Canaccord Genuity下调目标价至67美元，维持"买入"评级
今日重点评级关注：Northland Capital Markets：维持BrainsWay"跑赢大市"评级，目标价从15美元升至19美元；Lake Street：维持Hyperfine"买入"评级，目标价从1.5美元升至2美元
08-15 09:30
Passage Bio shares are trading lower. The company reported worse-than-expected Q2 EPS results.
Passage Bio shares are trading lower. The company reported worse-than-expected ...
08-12 21:20
Passage Bio Q2 EPS $(2.96) Misses $(0.21) Estimate
Passage Bio (NASDAQ:PASG) reported quarterly losses of $(2.96) per share which missed the analyst consensus estimate of $(0.21) by 1309.52 percent. This is a 41.85 percent increase over losses of $(5.09) per share from
08-12 19:08
Passage Bio Reports Second Quarter 2025 Financial Results and Provides Recent Business Highlights
Passage Bio reported financial results for Q2 2025 and key business highlights. Notably, the company completed dosing of Cohort 2 in the upliFT-D study and reported interim data showing continued robust increases in CSF PGRN levels and improved plasma NfL biomarkers. The amended study protocol was submitted to global trial sites and health authorities. Cash runway extends into 1Q 2027. Financials showed $57.6 million in cash, reduced R&D and G&A ...
08-12 11:00
Passage Bio Regains Nasdaq Compliance with Stock Price
Passage Bio ( ($PASG) ) just unveiled an update. On July 28, 2025, Passage Bio,...
07-30 05:31
Passage Bio shares are trading lower after the company announced a 1-for-20 reverse stock split.
Passage Bio shares are trading lower after the company announced a 1-for-20 rev...
07-10 20:28
Passage Bio Announces 1-for-20 Reverse Stock Split
Passage Bio announced a 1-for-20 reverse stock split to regain compliance with Nasdaq's $1.00 bid price requirement. The split will reduce outstanding shares from ~62.4 million to ~3.12 million, effective July 14, 2025, under symbol "PASG." Fractional shares will be rounded up, and no action is needed by registered or street name holders. The Company’s equity plans and employee stock purchase plan will be adjusted accordingly, without affecting s...
07-10 11:00
美股大行评级 | 潜在涨幅390.8%！HC Wainwright & Co.上调内克塔治疗目标价至120美元，维持"买入"评级
多家机构首予Amrize买入评级，目标价53~62美元；HC Wainwright & Co.上调内克塔治疗目标价至120美元，维持"买入"评级>>
06-25 08:39
Passage Bio Reports Interim Data From upliFT-D Showing Durable CSF PGRN Elevation And Reduced Plasma NfL Versus Natural History In FTD-GRN
PBFT02 continued to demonstrate robust, durable elevation in CSF PGRN levels and improvement in plasma NfL, a disease progression biomarker, compared to natural historyDose 2, 50% lower than Dose 1, substantially
06-23 19:07
